Contraceptive Technology Update – August 1, 2011
August 1, 2011
View Issues
-
Use of long-term methods moving up — How can you boost numbers?
(Editor's Note: Read the September 2011 edition of Contraceptive Technology Update for the second of our two-part special coverage of long-acting reversible contraceptives. Included in the upcoming issue is an in-depth look at the American College of Obstetricians and Gynecologists' new practice bulletin on the use of long-acting reversible contraceptives. The new recommendations offer guidance in selecting appropriate candidates for such methods and provide tips on managing clinical issues that might arise.) -
Treat HIV infection to protect partners
New research indicates that early initiation of antiretroviral treatment in people infected with HIV prevents them from transmitting the virus to their partners. -
Do OCs cause weight gain? No, says research
Thumbing through your inbox charts, you see your next patient is a 19-year-old who began use of oral contraceptives (OCs) about six months ago. When you talk with her in the examination room, however, you find that she has discontinued use of the Pill after she began to gain weight. -
Out-of-pocket expenses for OCs targeted
Findings from a new analysis indicate that women pay a higher percentage out of pocket when it comes to oral contraceptive (OC) expenditures. -
Boost teen HIV testing with free rapid tests
While adolescents are at risk for HIV, many forego testing. This lack of testing is a major public health concern, as more than 50% of HIV-infected adolescents do not know their infection status. -
HPV vaccines on time via text messaging
Research indicates that while many young women might initiate vaccination for human papillomavirus (HPV), they do not complete the three-injection course of treatment. -
OB/GYN Quarterly Update: Painful sex: Look at how far we've come, and yet how far we have left to go
Understanding sexual pain remains limited. With multiple etiologies and lack of evidence-based outcomes research, future investigations should focus on evaluating the intimacy of the couple, the partner relationship, and biomedical sources of pain such as the pelvic floor muscles. -
OB/GYN Quarterly Update: An outline: Prognosis and treatment of DIV
The authors performed a descriptive analysis of all cases of desquamative inflammatory vaginitis (DIV), defined as symptomatic vaginitis (discharge, dyspareunia, pruritus, burning, or irritation) associated with vaginal inflammation (such as focal or linear erosions), a vaginal pH higher than 4.5, and saline microscopy showing an increase in parabasal and inflammatory cells in the absence of an infectious etiology (such as trichomonas, candida, or bacterial vaginosis). -
Pharmacology Watch: FDA issues Multiple Drug Warnings
In this issue: FDA issues multiple drug safety alerts; ARBs and cancer risk; and FDA actions. -
Clinical Briefs in Primary Care supplement